A Study of Patient Preferences for the Treatment of Non–small Cell Lung Cancer in Western China

Background: Non–small cell lung cancer (NSCLC) is the most common histologic type of lung cancer, accounting for 70–85% of all lung cancers. It has brought a heavy burden of disease and financial cost to families, society, and the nation of China. Patients have differing preferences for treatment because of their varying physical conditions and socioeconomic backgrounds, which ultimately affects the choice of treatment as well as treatment outcomes. For better and sustained health outcomes, it is vital to understand patients' preferences. We can then provide medical services to match these preferences and needs rather than basing treatment on our clinical viewpoints alone. Objectives: The aim of this study was to elicit patient preferences for treatment using a discrete-choice experiment and to explore the value/importance that patients place on the different attributes of treatment in order to provide a basis for clinical decision making and patient health management. Methods: The study was conducted with NSCLC patients from three typical hospitals in southwestern China. After identifying patient-relevant treatment attributes via literature review and qualitative semi structured interviews, a discrete-choice experiment (DCE) including seven patient-relevant attributes was conducted using a fractional factorial SAS design. The empiric data analyses of patients were performed using mixed logit models. Results: NSCLC patients ( N = 202) completed a survey via a face-to-face interview. Among the seven attributes, the following were considered important: progression-free survival, disease control rate, cost, weakness/fatigue, and nausea/vomiting; mode of administration and rash were considered less important. A clear preference for an increase in progression-free survival and disease control rate was demonstrated. Compared with 5 months of progression-free survival, respondents were willing to pay more (19,860 RMB) for 11 months of progression-free survival (coef.: 0.687). Compared with a 60% rate of disease control, respondents were willing to pay more (19,940 RMB) for a 90% rate of disease control (coef.: 0.690). Conclusions: This study demonstrates the value of DCEs in determining patient preferences for the treatment of NSCLC. The results indicate that not only efficacy factors (such as progression-free survival and disease control rate) were considered but also other factors (such as side effects and treatment costs) and trade-offs between attributes were held to be important. These results are in accord with expectations and can provide evidence for more effective and efficient treatment results. Furthermore, the current results can increase benefits if the presented therapies can be designed, assessed, and chosen based on patient-oriented findings

Environmental health · Family medicine · Logistic regression · Lung cancer · Mixed logit · Nausea · Physical therapy · Population · Rash · Socioeconomic status · Economic and Environmental Valuation · Medicine · Patient-Provider Communication in Healthcare · Internal Medicine

• Preferences for public health insurance coverage of new anticancer drugs

  Open Access•Jingyi Meng, Feifei Yan et al.•BMC Public Health•2025

  Add to list

• Conjoint Analysis Applications in Health—a Checklist

  Open Access•John F P Bridges, A Brett Hauber et al.•Value in Health•2011

  Add to list

• Discrete Choice Experiments

  Open Access•Emily Lancsar, Denzil G Fiebig et al.•PharmacoEconomics•2017

  Add to list

• Conducting Discrete Choice Experiments to Inform Healthcare Decision Making

  Open Access•Emily Lancsar, Jordan J Louviere et al.•PharmacoEconomics•2008

  Add to list

• Discrete choice experiments in health economics

  Open Access•E W De Bekker-Grob, Esther W de Bekker‐Grob et al.•Health Economics•2012

  Add to list